Interviews

Concerns and precautions for a patient living with chronic fibrosing ILD with progressive phenotype during the coronavirus pandemic.

Based on findings from our COVID-19 Reopening the Workplace Survey, employers are increasing focus on safety, enhancing well-being programs, and providing flexibility to accommodate employees who may be at-risk or may shoulder a greater caregiving responsibility, said Regina Ihrke, senior director and wellbeing leader of Willis Towers Watson in North America.

Insurance coverage concerns and difficulties while seeking care for chronic fibrosing ILD with progressive phenotype.

The Affordable Care Act encourages preventive care, like cancer screenings, by eliminating copays, so that additional years will only see the number of lives saved grow, noted Fumiko Chino, MD, assistant attending radiation oncologist at Memorial Sloan Kettering Cancer Center in New York, in an interview prior to ASCO20 Virtual, this year’s annual meeting of the American Society of Clinical Oncology.
 

The management of chronic fibrosing ILD with progressive phenotype through immunosuppressants and oxygen is examined as well as the effect on lifestyle.

A patient perspective of initial diagnosis of chronic fibrosing ILD with progressive phenotype and the subsequent impact on quality of life.

Dawn Repola recalls her journey to diagnosis of chronic fibrosing interstitial lung disease with progressive phenotype and relays frustrations along the way.

To mark the 25th anniversary of The American Journal of Managed Care^®, we spoke with Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID). Fauci has been at NIAID for 36 years, and he gave a keynote address at the 6th International AIDS Conference in San Francisco in 1990. Here he speaks on progress that has been made in the fight against HIV and AIDS, from AZT to Truvada to undetectable viral loads; why there is no cure just yet; and how the first tumultuous years of the AIDS crisis shaped research for decades to come.

Using electronic health records of patients with cancer can provide a better understanding of which interventions and treatments are possible and can give patients the best outcomes, explained Blythe Adamson, PhD, MPH, principal quantitative scientist at Flatiron Health, in an interview for ASCO20 Virtual, this year’s annual meeting of the American Society of Clinical Oncology.
 

Even before the coronavirus disease 2019 (COVID-19) pandemic, the struggle to curb the opioid epidemic in the United States has produced disappointing outcomes. Now that COVID-19 and the resulting social distancing requirements have allowed the opioid epidemic to flourish, authors in the July issue of The American Journal of Managed Care^® suggest an alternative approach that emphasizes building resiliency and investing in social support. Marcelina Jasmine Silva, DO, joined us to discuss the current approaches to opioid use and potential lessons to be learned from COVID-19.